PCL Inc is a Korea-based company principally engaged in development and manufacture of vitro diagnostic medical device for immunological diagnosis. The Companyâ€™s products include blood bank screening products and quick diagnostic products. And the Company also provides platform services.

Employees

Sector

Biotechnology & Medical Research

More about the company

End-of-day quote Korea S.E. 21/03/2025			5-day change	1st Jan Change
6,040.00 ^KRW	-1.63%		-.--%	-

30/12/24	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
30/08/24	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI

Market Cap	16.8B 12.5M 11.21M 10.33M 9.38M 17.76M 1.17B 18.26M 124M 49.29M 628M 46.92M 45.93M 1.99B	P/E 2023	-7.17x	P/E 2024	-0.59x
Enterprise Value	23.83B 17.73M 15.9M 14.66M 13.31M 25.19M 1.66B 25.89M 175M 69.92M 891M 66.55M 65.14M 2.82B	EV / Sales 2023	22.8x	EV / Sales 2024	31.9x
Free-Float	98.99%	Yield 2023 *	-	Yield 2024	-

30/12/24	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
30/08/24	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI
22/08/24	PCL, Inc. announced that it expects to receive KRW 4.004999835 billion in funding	CI
25/06/24	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
21/06/24	Tiger Company Ltd. announced that it has received KRW 8.3 billion in funding from PCL, Inc.	CI
16/01/24	PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets	CI
26/12/23	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets	CI
21/12/23	PCL, Inc. announced that it expects to receive KRW 9.99999885 billion in funding from Global Emerging Markets	CI
15/12/23	PCL, Inc. announced that it expects to receive KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
31/05/23	South Korean Stocks Close Lower as Uncertainties Around US Debt Ceiling Deal Remain; PCL Loses 13%	MT
31/05/23	PCL to Raise 36 Billion Won via Share Issuance	MT
23/03/23	PCL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
29/12/22	PCL, Inc. announced that it has received KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.	CI

3 years	5,900	87,700
5 years	5,900	340,000
10 years	5,900	523,333.33

PCL, Inc. Stock

Stocks

A241820

KR7241820000

Biotechnology & Medical Research

Valuation: PCL, Inc.

Latest news: PCL, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: PCL, Inc.

Bio Diagnostics & Testing

Financials

Company Profile

Manager	Title	Age	Since
So-Yeon Kim CEO	Chief Executive Officer	55	-
Seong-Woo Lee SAM	Sales & Marketing	42	28/03/2024
Mu-Yong So AUD	Comptroller/Controller/Auditor	53	28/03/2024

Director	Title	Age	Since
So-Yeon Kim BRD	Director/Board Member	55	-
Chul-Joon Kim BRD	Director/Board Member	74	-
Mu-Yong So BRD	Director/Board Member	53	28/03/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCL, INC.	-1.63%	-.--%	-.--%	-89.00%	12.49M
WUXI APPTEC CO., LTD.	+0.01%	+8.40%	+58.48%	+69.01%	68.22B
ARGENX SE	+1.22%	+10.23%	+18.35%	+87.67%	59.82B
LONZA GROUP AG	+0.24%	+1.97%	+24.62%	+94.87%	56.07B
BEONE MEDICINES AG	+1.60%	+19.44%	+28.80%	+112.95%	47.67B
IQVIA HOLDINGS INC.	-1.32%	+4.78%	+29.15%	+40.40%	45.95B
REVOLUTION MEDICINES, INC.	-3.54%	-0.60%	+207.76%	+879.50%	43.29B
CELLTRION, INC.	-3.33%	+5.73%	+23.28%	+47.32%	35.66B
GENMAB A/S	-2.19%	-3.16%	+93.83%	+63.14%	34.73B
INSMED INCORPORATED	+2.92%	+14.41%	-37.74%	+403.12%	25.47B
Average	-0.63%	+4.46%	+44.65%	+170.90%	42B
Weighted average by Cap.	-0.45%	+5.40%	+51.10%	+179.26%

	2023	2024
Net sales	8.43B 6.27M 5.62M 5.18M 4.71M 8.91M 588M 9.16M 62.07M 24.73M 315M 23.54M 23.04M 996M	1.25B 927K 832K 766K 696K 1.32M 86.93M 1.35M 9.18M 3.66M 46.58M 3.48M 3.41M 147M
Net income	-20.32B -15.12M -13.56M -12.49M -11.35M -21.47M -1.42B -22.07M -150M -59.6M -759M -56.73M -55.53M -2.4B	-52.34B -38.94M -34.92M -32.18M -29.23M -55.32M -3.65B -56.86M -385M -154M -1.96B -146M -143M -6.18B
Net Debt	7.2B 5.36M 4.81M 4.43M 4.02M 7.61M 503M 7.83M 53.04M 21.13M 269M 20.12M 19.69M 851M	7.03B 5.23M 4.69M 4.32M 3.93M 7.43M 490M 7.64M 51.76M 20.62M 263M 19.63M 19.21M 831M